Archives

Landmark trial for novel Alzheimer’s disease treatment

9 October 2018

Professor Martin Rossor, NIHR National Director for Dementia Research

This story was first published on the NIHR website. The first clinical trial of a completely novel and unprecedented approach to modifying the progression of Alzheimer’s disease has opened at the NIHR University College London Hospitals (UCLH) Clinical Research Facility. The Depletion of serum amyloid P component in Alzheimer’s disease (DESPIAD) trial will test whether […]

The European Prevention of Alzheimer’s Dementia (EPAD) Longitudinal Cohort Study

26 April 2018

epad

EPAD is a major study which takes place all over Europe, and is led from the University of Edinburgh. It is one of the biggest dementia studies in the world and as such, it is hugely important that researchers are able to recruit lots of volunteers into the study. We caught up with Sarah Gregory, […]

The Suvorexant (MK-4305) Insomnia in Alzheimer’s Disease study

26 June 2017

What are the main aims of the study? Many people with Alzheimer’s experience changes in their sleep patterns. Scientists do not completely understand why this happens. While changes in memory and behaviour may be expected with Alzheimer’s, sleep changes are not always anticipated. Sleep changes in Alzheimer’s may include the following: • Difficulty sleeping. Many […]

Why do we need biomarkers for Alzheimer’s disease?

29 September 2016

This blog was written by Professor Simon Lovestone, Professor of Translational Neuroscience at the University of Oxford and was originally featured on the NIHR website.    There is an increasing focus on finding biomarkers, or tests, for dementia. Whether in the contents pages of journals, or in conference programmes, biomarker research seems to be the order […]

The ENGAGE study

19 July 2016

The latest clinical trial to be added to Join Dementia Research is ENGAGE, from Biogen Inc. Part of an international study, it is looking to determine whether a new medication called Aducanumab, can slow progression of early Alzheimer’s disease, as well as investigating whether it’s safe to use in patients. Researchers are looking for volunteers […]

Number of Alzheimer’s clinical trials almost doubles in 3 years

According to latest figures, the number of drug trials to treat Alzheimer’s disease across the globe has almost doubled since 2013¹. In the UK, there are now 19 drug studies investigating potential new treatments for Alzheimer’s and other dementias², testing treatments that aim to be the first to slow or stop the progression of the […]

The DARet Study

11 July 2016

Sometimes patients treated for Parkinson’s disease can have problems with memory and learning. This is thought to be due to a decrease in their dopamine levels due to their disease. Dopamine is a naturally occurring chemical in the brain. Patients with Parkinson’s disease are given many drugs to increase their dopamine levels back to normal, […]

INMiND-02 Study

6 June 2016

The INMiND-02 Study is a new trial looking at whether a drug that is currently used to treat arthritis could help the memory function of people with Mild Cognitive Impairment (MCI). What are the main aims of the INMiND-02 study? To see if a drug (Etanercept) already used for the treatment of rheumatoid arthritis might […]

MINDSET Study

19 May 2016

The MINDSET Study, sponsored by Axovant Sciences Ltd., is a new study looking at whether an innovatory new drug could be used to help improve the everyday lives of mild-to-moderate Alzheimer’s patients. What are the main aims? The purpose of this study is to understand whether an investigational drug known as ‘RVT 101’ improves Alzheimer’s […]

The ‘AFFECT’ Study

26 February 2016

The ‘AFFECT’ study is the first large-scale research study that is a collaboration between researchers in Northern Ireland, and staff at the Dementias and Neurodegenerative Specialty  in England. It is also being jointly funded by the Alzheimer’s Society and British Heart Foundation. Did you know that after Alzheimer’s Disease, Vascular Dementia is the most common […]

1 2
get_header(); ?>

Archives

1 2